# CTXR catalysts: Citius Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ctxr/catalysts

> Citius Pharmaceuticals, Inc. (CTXR) has no upcoming catalysts in this calendar. The latest recorded is the Citius Pharmaceuticals, Inc. earnings report, August 14, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Citius Pharmaceuticals, Inc. |
| Ticker | CTXR (Nasdaq) |
| SEC CIK | 1506251 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ctxr |

## Cash runway

Cash $17.0M as of 2026-06-30; quarterly burn $8.7M; about 5.9 months of runway at that rate (XBRL company facts, accession 0001213900-26-090185).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 27, 2022 | [Citius Pharmaceuticals, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "The BLA was filed with the FDA on September 27, 2022, refiled on February 13, 2024, and accepted by the FDA on March 18, 2024 and we received a BLA approval on August 8, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1506251/000121390025014321/ea0230774-10q_citius.htm)) |
| Jul 2023 | [Citius Pharmaceuticals, Inc. complete response letter (CRL)](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed, complete response letter | "In July 2023, the FDA issued a complete response letter ("CRL") requiring us to incorporate enhanced product testing and additional controls agreed to with the FDA during the market application review." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1506251/000121390025125333/ea0270098-10k_citius.htm)) |
| July 28, 2023 | [Lymphir (denileukin diftitox-cxdl) complete response letter (CRL)](https://sec-api.dev/pdufa/denileukin-diftitox-cxdl) | CTXR |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761312Orig1s000OtherActionLtrs.pdf%22)) |
| May 2024 | [Citius Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed, positive | "In May 2024, the Company announced positive topline results of the trial." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1506251/000121390026047296/ea0287618-424b5_citius.htm)) |
| Aug 2024 | [CITI-002 FDA approval](https://sec-api.dev/pdufa/citi-002) | CTXR |  | completed, approved | "In August 2024, the FDA approved" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390024102833/ea022238001ex99-1_citius.htm)) |
| November 11, 2024 | [KEYTRUDA® (pembrolizumab) trial start](https://sec-api.dev/pdufa/pembrolizumab) | CTXR | recurrent solid tumors | completed | "(Nasdaq: CTOR), today announced promising preliminary results from an ongoing investigator-initiated Phase I clinical trial evaluating the safety and efficacy of a combined regimen of pembrolizumab and LYMPHIR™ (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390024096268/ea022067001ex99-1_citius.htm)) |
| December 27, 2024 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390024113158/ea022616101ex99-1_citius.htm)) |
| May 14, 2025 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390025043362/ea024197401ex99-1_citius.htm)) |
| August 12, 2025 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for its fiscal third quarter ended June 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390025075034/ea025289901ex99-1_citius.htm)) |
| December 23, 2025 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390025125413/ea027077601ex99-1_citius.htm)) |
| February 9, 2026 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "N.J., February 13, 2026- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390026015895/ea027694801ex99-1_citius.htm)) |
| March 10, 2026 | [Citius Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed, positive | "On March 10, 2026, Citius Oncology announced positive topline results from a completed investigator-initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1506251/000121390026090185/ea0301919-10q_citius.htm)) |
| May 15, 2026 | [Citius Pharmaceuticals, Inc. trial start](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Announced positive topline results from two investigator-initiated Phase 1 studies, including:" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/ea029103701ex99-1.htm)) |
| May 15, 2026 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported business and financial results for the fiscal second quarter ended March 31, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/ea029103701ex99-1.htm)) |
| August 14, 2026 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390026090181/ea030222701ex99-1.htm)) |

## Drugs

- [CITI-002](https://sec-api.dev/pdufa/citi-002): 
- [Lymphir (denileukin diftitox-cxdl)](https://sec-api.dev/pdufa/denileukin-diftitox-cxdl): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ctxr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CTXR catalysts: Citius Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ctxr/catalysts

```bibtex
@misc{secapidev_companies_ctxr_catalysts_20261116,
  title        = {CTXR catalysts: Citius Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ctxr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ctxr_catalysts_20261116","title":"CTXR catalysts: Citius Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ctxr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
